Xiaokui Mo, Ph.D. - Publications

2002 Ohio State University, Columbus, Columbus, OH 
Biochemistry, Molecular Biology

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Trikha P, Plews RL, Stiff A, Gautam S, Hsu V, Abood D, Wesolowski R, Landi I, Mo X, Phay J, Chen CS, Byrd J, Caligiuri M, Tridandapani S, Carson W. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology. 5: e1214787. PMID 27757311 DOI: 10.1080/2162402X.2016.1214787  0.96
2016 Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson Md GA. A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. Molecular Cancer Therapeutics. PMID 27458141 DOI: 10.1158/1535-7163.MCT-15-0879  0.96
2016 Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE, Caligiuri MA. NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Reports. PMID 27373165 DOI: 10.1016/j.celrep.2016.05.095  0.96
2016 Browning RL, Byrd WH, Gupta N, Jones J, Mo X, Hertlein E, Yu L, Muthusamy N, Byrd JC. Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunology Research. PMID 27287425 DOI: 10.1158/2326-6066.CIR-15-0291  0.96
2016 Gautam S, Fatehchand K, Elavazhagan S, Reader BF, Ren L, Mo X, Byrd JC, Tridandapani S, Butchar JP. Reprogramming nurse-like cells with Interferon-γ to interrupt chronic lymphocytic leukemia cell survival. The Journal of Biological Chemistry. PMID 27226587 DOI: 10.1074/jbc.M116.723551  0.96
2016 McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia Oncoimmunology. DOI: 10.1080/2162402X.2016.1226720  0.96
2015 Fatehchand K, Ren L, Elavazhagan S, Fang H, Mo X, Vasilakos JP, Dietsch GN, Hershberg RM, Tridandapani S, Butchar JP. Toll-like receptor 4 ligands down-regulate FcγRIIb via MARCH3-mediated ubiquitination. The Journal of Biological Chemistry. PMID 26694610 DOI: 10.1074/jbc.M115.701151  0.96
2015 Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE, Butchar JP, Tridandapani S. Analysis of the effects of the Btk inhibitor ibrutinib on monocyte FcγR function. The Journal of Biological Chemistry. PMID 26627823 DOI: 10.1074/jbc.M115.687251  0.96
2014 Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CS. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Research. 74: 4783-95. PMID 24994714 DOI: 10.1158/0008-5472.CAN-14-0135  0.96
2014 Forget MA, Voorhees JL, Cole SL, Dakhlallah D, Patterson IL, Gross AC, Moldovan L, Mo X, Evans R, Marsh CB, Eubank TD. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. Plos One. 9: e98623. PMID 24892425 DOI: 10.1371/journal.pone.0098623  0.96
2014 Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. Mabs. 6: 749-55. PMID 24594909 DOI: 10.4161/mabs.28282  0.96
2014 Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, ... ... Mo X, et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Research. 74: 1752-65. PMID 24453002 DOI: 10.1158/0008-5472.CAN-13-0884  0.96
2014 Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 28: 1501-10. PMID 24445867 DOI: 10.1038/leu.2014.32  0.96
2013 Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6716-29. PMID 24132923 DOI: 10.1158/1078-0432.CCR-13-0842  0.96
2013 Wang X, Yu B, Ren W, Mo X, Zhou C, He H, Jia H, Wang L, Jacob ST, Lee RJ, Ghoshal K, Lee LJ. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 690-8. PMID 24121065 DOI: 10.1016/j.jconrel.2013.09.027  0.96
2013 Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Mo X, Wehr A, Lehman A, Fernandez S, Kaur B, Chiocca EA. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5952-9. PMID 24056786 DOI: 10.1158/1078-0432.CCR-12-3588  0.96
2013 Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani S. Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. The Journal of Biological Chemistry. 288: 26800-9. PMID 23902770 DOI: 10.1074/jbc.M113.485185  0.96
2013 Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, ... Mo X, et al. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. Mabs. 5: 723-35. PMID 23883821 DOI: 10.4161/mabs.25282  0.96
2013 Price RL, Song J, Bingmer K, Kim TH, Yi JY, Nowicki MO, Mo X, Hollon T, Murnan E, Alvarez-Breckenridge C, Fernandez S, Kaur B, Rivera A, Oglesbee M, Cook C, et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Research. 73: 3441-50. PMID 23729642 DOI: 10.1158/0008-5472.CAN-12-3846  0.96
2013 Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials. 34: 6185-93. PMID 23726226 DOI: 10.1016/j.biomaterials.2013.04.063  0.96
2013 Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ. Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2984-94. PMID 23549869 DOI: 10.1158/1078-0432.CCR-12-2008  0.96
2013 Voorhees JL, Tarr AJ, Wohleb ES, Godbout JP, Mo X, Sheridan JF, Eubank TD, Marsh CB. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. Plos One. 8: e58488. PMID 23520517 DOI: 10.1371/journal.pone.0058488  0.96
2013 Yu J, Peng Y, Wu LC, Xie Z, Deng Y, Hughes T, He S, Mo X, Chiu M, Wang QE, He X, Liu S, Grever MR, Chan KK, Liu Z. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. Plos One. 8: e55934. PMID 23457487 DOI: 10.1371/journal.pone.0055934  0.96
2013 Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. Journal of Immunology (Baltimore, Md. : 1950). 190: 2702-11. PMID 23418626 DOI: 10.4049/jimmunol.1202588  0.96
2013 Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, Waclaw R, Beullens M, Nakano I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells (Dayton, Ohio). 31: 1051-63. PMID 23404835 DOI: 10.1002/stem.1358  0.96
2013 Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy N. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 347-56. PMID 23209030 DOI: 10.1158/1078-0432.CCR-12-2046  0.96
2013 Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood. 121: 136-47. PMID 23165478 DOI: 10.1182/blood-2012-01-407742  0.96
2012 Chen HZ, Ouseph MM, Li J, Pécot T, Chokshi V, Kent L, Bae S, Byrne M, Duran C, Comstock G, Trikha P, Mair M, Senapati S, Martin CK, Gandhi S, ... ... Mo X, et al. Canonical and atypical E2Fs regulate the mammalian endocycle. Nature Cell Biology. 14: 1192-202. PMID 23064266 DOI: 10.1038/ncb2595  0.96
2012 Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 120: 4621-34. PMID 23034282 DOI: 10.1182/blood-2012-05-429506  0.96
2012 Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, ... ... Mo X, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 21: 694-708. PMID 22624718 DOI: 10.1016/j.ccr.2012.03.040  0.96
2011 Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, Kaou M, Zhong Y, Johnson AJ, Lucas DM, Heerema NA, Hagan J, Mo X, Jarjoura D, Byrd JC, et al. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood. 118: 6132-40. PMID 22001392 DOI: 10.1182/blood-2011-01-323147  0.96
2011 Muthusamy N, Breidenbach H, Andritsos L, Flynn J, Jones J, Ramanunni A, Mo X, Jarjoura D, Byrd JC, Heerema NA. Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genetics. 204: 77-83. PMID 21494579 DOI: 10.1016/j.cancergen.2010.12.006  0.96
2011 Bai LY, Ma Y, Kulp SK, Wang SH, Chiu CF, Frissora F, Mani R, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy N. OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway. British Journal of Haematology. 153: 623-33. PMID 21470196 DOI: 10.1111/j.1365-2141.2010.08443.x  0.96
2010 Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula SV, Mo X, Chemudupati M, Kanneganti TD, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson WE, Byrd JC, Tridandapani S. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2065-75. PMID 20332325 DOI: 10.1158/1078-0432.CCR-09-2591  0.96
2010 Biswas S, Zhao X, Mone AP, Mo X, Vargo M, Jarjoura D, Byrd JC, Muthusamy N. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leukemia Research. 34: 925-31. PMID 20171736 DOI: 10.1016/j.leukres.2010.01.020  0.96
2010 Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 115: 1204-13. PMID 19965644 DOI: 10.1182/blood-2009-06-229039  0.96
2010 Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 115: 2619-29. PMID 19965642 DOI: 10.1182/blood-2009-09-242438  0.96
2003 Mo X, Marzluf GA. Cooperative action of the NIT2 and NIT4 transcription factors upon gene expression in Neurospora crassa. Current Genetics. 42: 260-7. PMID 12589465 DOI: 10.1007/s00294-002-0362-3  0.96
Show low-probability matches.